Excalipoint Therapeutics is a clinical-stage biotechnology company focused on discovering and developing T-cell engager (TCE) therapies for oncology and immunology indications. Its pipeline includes tri- and multi-specific antibody programs such as EXP011 (CTM012) targeting DLL3/CD3/4-1BB—entered Phase I/II with first patient dosed in October 2025—EXP012 (CTM013) targeting CDH17/CD3/4-1BB, and additional programs (EXP016, EXP017, EP101, EXP015) built on its TOPAbody, Immune Shield, and Pro-TCE platform technologies. The company is led by CEO Lei Fang and CFO Jielun Zhu. Following the $68.7M Seed raise, Excalipoint intends to use the funds to advance its proprietary platforms and progress its pipeline programs through clinical development.

Total raised

$28M

Funding rounds

1

Latest round

Seed

Latest activity

Mar 2026